PropertyValue
is ?:annotates of
?:authorAffiliation
  • [\'Drug Safety Research Unit, Bursledon Hall, Blundell Lane, Southampton, SO31 1AA, UK. vicki.osborne@dsru.org.\', \'School of Pharmacy and Biomedical Sciences, University of Portsmouth, Portsmouth, UK. vicki.osborne@dsru.org.\', \'Drug Safety Research Unit, Bursledon Hall, Blundell Lane, Southampton, SO31 1AA, UK.\', \'School of Pharmacy and Biomedical Sciences, University of Portsmouth, Portsmouth, UK.\']
?:citedBy
  • -1
?:creator
?:doi
  • 10.1007/s40264-020-00966-9
?:doi
?:hasPublicationType
?:journal
  • Drug safety
is ?:pmid of
?:pmid
?:pmid
  • 32578156
?:publication_isRelatedTo_Disease
?:rankingScore_SJR
  • 1.447
?:rankingScore_hIndex
  • 112
is ?:relation_isRelatedTo_publication of
?:title
  • Lopinavir-Ritonavir in the Treatment of COVID-19: A Dynamic Systematic Benefit-Risk Assessment.
?:type
?:year
  • 2020

Metadata

Anon_0  
<http://www.w3.org/1999/02/22-rdf-syntax-ns#type> <http://purl.org/net/provenance/ns#DataItem>
<http://www.w3.org/1999/02/22-rdf-syntax-ns#type> <http://www.w3.org/2004/03/trix/rdfg-1/Graph>
<http://xmlns.com/foaf/0.1/primaryTopic> <https://research.tib.eu/covid-19/entity/32578156>
<http://xmlns.com/foaf/0.1/topic> Anon_0
<http://www.ontologydesignpatterns.org/cp/owl/informationrealization.owl#realizes> <https://research.tib.eu/covid-19/data/entity/32578156>
<http://purl.org/net/provenance/ns#createdBy>
Anon_1   (more)
expand all